Weight-loss drugmaker Novo Nordisk's shares fall on disappointing study | Jordan Times
Novo Nordisk shares fell 22% after a weight-loss drug study showed Cagrisema users lost 22.7% vs. 2.3% with a placebo, below the expected 25%. Despite this, the company plans to explore Cagrisema's potential further.
Highlighted Terms
Related News
Weight-loss drugmaker Novo Nordisk's shares fall on disappointing study | Jordan Times
Novo Nordisk shares fell 22% after a weight-loss drug study showed Cagrisema users lost 22.7% vs. 2.3% with a placebo, below the expected 25%. Despite this, the company plans to explore Cagrisema's potential further.